Ropinirole extended-release

Drug Profile

Ropinirole extended-release

Alternative Names: Requip CR; Requip LP; Requip Modutab/XL 24-hour; Requip XL; Requip XR; RequipP XL 24-hour Extended-Release Tablets; Ropinirole controlled-release; Ropinirole CR; Ropinirole ER; Ropinirole LP; Ropinirole PR; Ropinirole prolonged-release; Ropinirole XL; Ropinirole XR; SKF 101468A

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Amines; Antiparkinsonians; Indoles; Sleep disorder therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Parkinson's disease; Restless legs syndrome

Most Recent Events

  • 17 Oct 2017 GlaxoSmithKline terminates a phase III trial in Parkinson's disease in Japan (PO) (NCT01929317)
  • 01 Jun 2015 GlaxoSmithKline completes a phase III trial in Parkinson's disease in Japan (PO) (NCT01929317)
  • 10 Jan 2014 Phase-III clinical trials in Parkinson's disease (monotherapy) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top